Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2013 San Antonio Breast Cancer Symposium (SABCS) /
BETH study: highly effective treatment option for patients with HER2 breast cancer

9th - 11th Dec 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.12.13
Views: 3392
Rating:

Dr Dennis Slamon - University of California, Los Angeles

During a press conference at the SABCS 2013, Dr Dennis Slamon presents data from the recent BETH study.

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumour size and whether or not disease has spread to the lymph nodes, according to results from the study.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation